J. Zhou

Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study

R. Preston, Y. Horsmans, J. Zhou, 2018, Clinical Pharmacokinetics.

Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors

J. Nedelman, E. Hurh, J. Zhou, 2016, Cancer Chemotherapy and Pharmacology.

A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug–Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients

J. Zhou, S. Rebello, H. Einolf, 2017, Drug Metabolism and Disposition.

Exposure‐Response Analysis of Sonidegib (LDE225), an Oral Inhibitor of the Hedgehog Signaling Pathway, for Effectiveness and Safety in Patients With Advanced Solid Tumors

E. Hurh, J. Zhou, M. Quinlan, 2016, Journal of clinical pharmacology.

Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid tumors

E. Hurh, J. Zhou, M. Quinlan, 2016, European Journal of Clinical Pharmacology.

A physiologically-based pharmacokinetic modeling approach to predict drug-drug interactions of sonidegib ( LDE 225 ) with perpetrators of CYP 3 A in cancer patients

J. Zhou, S. Rebello, H. Einolf, 2016 .